0001567619-19-005678.txt : 20190228
0001567619-19-005678.hdr.sgml : 20190228
20190228193559
ACCESSION NUMBER: 0001567619-19-005678
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190226
FILED AS OF DATE: 20190228
DATE AS OF CHANGE: 20190228
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kramer Robert
CENTRAL INDEX KEY: 0001380956
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33137
FILM NUMBER: 19646133
MAIL ADDRESS:
STREET 1: 2273 RESEARCH BLVD, SUITE 400
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Emergent BioSolutions Inc.
CENTRAL INDEX KEY: 0001367644
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 141902018
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 PROFESSIONAL DR, SUITE 400
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
BUSINESS PHONE: 240-631-3200
MAIL ADDRESS:
STREET 1: 400 PROFESSIONAL DR, SUITE 400
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
4
1
doc1.xml
FORM 4
X0306
4
2019-02-26
0
0001367644
Emergent BioSolutions Inc.
EBS
0001380956
Kramer Robert
400 PROFESSIONAL DR, SUITE 400
GAITHERSBURG
MD
20879
0
1
0
0
President and COO
Common Stock
2019-02-26
4
F
0
565
61.01
D
90607
D
Common Stock
2019-02-26
4
A
0
11801
0.00
A
102408
D
Common Stock
2019-02-26
4
A
0
11801
0.00
A
114209
D
Common Stock
2019-02-27
4
F
0
779
57.98
D
113430
D
Common Stock
2019-02-28
4
F
0
1941
58.71
D
111489
D
Employee Stock Option (Right to Buy)
61.01
2019-02-26
4
A
0
47197
61.01
A
2026-02-25
Common Stock
47197
47197
D
Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated.
These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted net income as a percentage of total GAAP revenue for the 2021 fiscal year, as certified by the Compensation Committee following the performance period.
Vests in three equal installments beginning on the day prior to the anniversary date of the grant.
/s/ S. Scott Lieberman, Attorney-in-fact
2019-02-28